According to SA analyst Kumquat Research, “AbbVie shares dropped nearly 10% after its schizophrenia drug emraclidine failed in late-stage trials. The market reaction appears excessive and presents a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback